EARLY ANALYSES OF NEWLY APPROVED DRUGS MAY PRODUCE BIASED CONCLUSIONS

OBJECTIVES: Real-world health care data are increasingly used to study the effectiveness of interventions in large, heterogeneous patient populations. It is important to understand what biases could arise in the analysis of real-world data collected shortly after a new treatment is introduced, espec...

Ausführliche Beschreibung